Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Adding IVIG to standard prednisone therapy significantly improved outcomes in newly diagnosed idiopathic inflammatory myopathies (IIMs), a small clinical trial found. Patients on the combo reached moderate improvement in just 4 weeks vs. 12 weeks on prednisone alone, and 91% hit that milestone by week 12 compared to 53% on placebo. The findings suggest many new IIM patients may be undertreated with steroids alone.
A small but compelling randomized trial published in JAMA Neurology suggests that adding intravenous immunoglobulin (IVIG) to high-dose prednisone could meaningfully change how newly diagnosed idiopathic inflammatory myopathies (IIMs) are treated. IIMs are immune-driven disorders that attack skeletal muscles, and while steroids are the go-to first-line therapy, improvement is often slow and incomplete.
The TIME IS MUSCLE trial enrolled 44 adults across IIM subtypes — including dermatomyositis and immune-mediated necrotizing myopathy — and randomized them to receive IVIG or placebo on top of standard prednisone. The results were striking: the IVIG group hit moderate improvement in just 4 weeks vs. 12 weeks for placebo, with better muscle strength, lower disease activity, and less disability across the board.
By the Numbers:
Why it matters: These findings challenge the current standard of prednisone monotherapy for new IIM diagnoses, suggesting earlier, more intensive treatment could dramatically speed recovery. However, thromboembolic risks — including one DVT and one sudden death — mean careful patient monitoring is essential. Longer-term data at 6 and 12 months are still pending.
